Immunofluorescence analysis showed that G-Rh2 treatment obviously inhibited the expression of CD31 (Fig. 4I), indicating that G-Rh2 inhibited tumor lymph angiogenesis. The gene discussed is PECAM1; the disease is neoplasm.